COMMUNIQUÉS West-GlobeNewswire
-
XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease
12/12/2018 - 14:30 -
PSIQ Executes Agreement with Saboneto Soap Company, Amid Farm Bill, to Exclusively Produce PSIQ’s Hemp Infused Organic Soap with Dead Sea Salts
12/12/2018 - 14:30 -
Precipio Reports Strong Mid-Quarter Growth
12/12/2018 - 14:15 -
Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®
12/12/2018 - 14:01 -
HealthEC Announces Beaumont ACO as New Client for Population Health Management Solution
12/12/2018 - 14:00 -
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
12/12/2018 - 14:00 -
CTD Holdings to Present at WORLD Symposium on Lysosomal Storage Diseases
12/12/2018 - 14:00 -
IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States
12/12/2018 - 14:00 -
Progressive Care Inc. Announces Record-Breaking November 2018
12/12/2018 - 14:00 -
AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
12/12/2018 - 14:00 -
Sera Prognostics Receives New York State Approval for PreTRM® Testing
12/12/2018 - 14:00 -
Maverick Technology Solutions’ ROSINBOMB™ Rocket Featured in Forbes
12/12/2018 - 14:00 -
Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity
12/12/2018 - 14:00 -
Sport Endurance Announces Closing of $2.8 Million Financing to Explore Strategic Alternatives in the CBD, Hemp and Legal Cannabis Industries
12/12/2018 - 14:00 -
Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin
12/12/2018 - 14:00 -
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder
12/12/2018 - 13:35 -
KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
12/12/2018 - 13:30 -
Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS™ Device
12/12/2018 - 13:05 -
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
12/12/2018 - 13:00
Pages